Compare NPO & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPO | XENE |
|---|---|---|
| Founded | 2002 | 1996 |
| Country | United States | Canada |
| Employees | 4000 | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 5.7B |
| IPO Year | 2002 | 2014 |
| Metric | NPO | XENE |
|---|---|---|
| Price | $299.79 | $38.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $278.33 | $68.55 |
| AVG Volume (30 Days) | 127.2K | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.46% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.55 | N/A |
| Revenue | ★ $1,532,000,000.00 | $311,000.00 |
| Revenue This Year | $12.31 | N/A |
| Revenue Next Year | $6.39 | $2,496.48 |
| P/E Ratio | $116.15 | ★ N/A |
| Revenue Growth | ★ 16.98 | N/A |
| 52 Week Low | $202.00 | $35.97 |
| 52 Week High | $390.42 | $72.66 |
| Indicator | NPO | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 47.14 | 13.74 |
| Support Level | $293.51 | N/A |
| Resistance Level | $303.49 | $45.39 |
| Average True Range (ATR) | 9.07 | 1.79 |
| MACD | 1.38 | -2.23 |
| Stochastic Oscillator | 68.28 | 2.00 |
Enpro Inc formerly EnPro Industries Inc is a United States-based company that designs, develops, manufactures, and markets proprietary engineered industrial products. The company operates through two segments: Sealing Technologies, which derives maximum revenue, manufactures and markets sealing products, wheel-end components & systems; and Advanced Surface Technologies, which manufactures wafer processing sub-systems, thin-film coatings, optical filters, and other services like cleaning, coating, testing, and refurbishment. Its geographical segments are the United States, Europe, and other foreign countries.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.